Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours

BACKGROUND: The antiproliferative activity of octreotide LAR in neuroendocrine tumours (NETs) has been demonstrated by small retrospective studies and confirmed by a prospective phase III trial (PROMID). However, there are limited data about the duration and predictors of response. The aim of our re...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Laskaratos, Faidon-Marios, Walker, Martin, Naik, Keval, Maragkoudakis, Emmanouil, Oikonomopoulos, Nikolaos, Grant, Lee, Meyer, Tim, Caplin, Martyn, Toumpanakis, Christos
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2016
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5129835/
https://ncbi.nlm.nih.gov/pubmed/27811856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.349
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars